SpringWorks Therapeutics (SWTX) Aktie Kurs
SpringWorks Therapeutics Kurs
Intäkterna har vuxit med 3,4 % per år under de senaste 24 åren till 191,59 M USD. Vinst per aktie har vuxit med 9,1 % per år under de senaste 9 åren. SpringWorks Therapeuticss nettovinstmarginal ligger på −134,7 %, ned från −126,4 % för några år sedan. Analytikernas mediankursmål är 47,94 USD, vilket är över nuvarande kurs med 2,0 %. Av 11 analytiker ger 0 köpråd — den samlade bedömningen är Behåll.
SpringWorks Therapeutics aktiekurs
Hämta dessa data via Eulerpool API
100 000 anrop/mån gratis · inget kreditkort
SpringWorks Therapeutics affärsmodell och aktieanalys
Vanliga frågor om SpringWorks Therapeutics-aktien
The business model of SpringWorks Therapeutics Inc. is focused on developing and commercializing innovative targeted therapies for patients with severe rare diseases and cancer. The company aims to identify promising drug candidates and advance them through clinical development to address unmet medical needs. SpringWorks Therapeutics Inc. collaborates with both academic institutions and industry partners to leverage its expertise and optimize the development of potential treatments. By utilizing targeted therapies, the company aims to provide effective and personalized solutions for patients, with a focus on improving their overall quality of life.
SpringWorks Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of SpringWorks Therapeutics Inc in the market include companies like Novartis, Pfizer, and Roche.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing life-changing therapies for patients with severe rare diseases and cancer. Founded in 2017, SpringWorks Therapeutics is committed to delivering innovative treatments by leveraging its strategic collaborations and advanced drug development expertise. With a diverse pipeline of investigational therapies, the company aims to address unmet medical needs and improve patients' lives globally. SpringWorks Therapeutics Inc has made significant progress in its mission to transform the lives of patients through its dedication to scientific excellence and groundbreaking research in the field of precision medicine.
Some significant milestones achieved by SpringWorks Therapeutics Inc include the approval of their lead product candidate, Nirogacestat, for the treatment of desmoid tumors by the U.S. FDA. The company also received Fast Track and Orphan Drug designations for Nirogacestat, which further highlights its potential in addressing unmet medical needs. Additionally, SpringWorks Therapeutics Inc has successfully initiated multiple clinical trials evaluating various therapies for rare cancers and genetic diseases. These accomplishments demonstrate the company's commitment towards advancing innovative treatments and improving patients' lives.
SpringWorks Therapeutics Inc is primarily present in the United States.
SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe rare diseases and cancer. The company's core values include dedication, integrity, and collaboration in their pursuit of discovering novel treatments. With a patient-centric approach, SpringWorks Therapeutics aims to improve the lives of individuals affected by these debilitating conditions. They prioritize scientific excellence and ethical practices to deliver safe and effective therapies. Through strategic partnerships and pioneering research, the company strives to bring hope and transformative solutions to patients in need. SpringWorks Therapeutics Inc is committed to making a lasting impact in the lives of patients and their families.
Analytiker sätter för närvarande ett genomsnittligt riktkurs på 53,33 USD för SpringWorks Therapeutics-aktien (median: 47,94 USD), vilket innebär +13,5 % mot senaste kurs. Konsensus baseras på 11 analytikerbetyg.
11 analytiker betygsätter för närvarande SpringWorks Therapeutics-aktien: 0 rekommenderar köp, 8 behåll och 3 sälj. För 2026 väntar sig analytiker att SpringWorks Therapeutics genererar intäkter på 612,33 M USD och vinst per aktie på −0,84 USD.
Omräknat till aktuell växelkurs handlas SpringWorks Therapeutics-aktien till 41,98 EUR (46,99 USD).
SpringWorks Therapeutics-aktien (SWTX) är noterad på 1 börser, bland annat: NASDAQ (SWTX).
SpringWorks Therapeutics is a biopharmaceutical company focused on developing therapeutics for patients with rare severe diseases. The business model involves developing innovative therapies with high medical necessity and making them accessible to the market. The company specializes in three main areas: oncology, inherited metabolic disorders, and neurological disorders. SpringWorks aims to develop new and effective therapies for each of these diseases. In the oncology sector, SpringWorks utilizes its expertise in drug discovery and development to create innovative cancer therapies. One of the leading products is Nirogacestat, a Notch pathway inhibitor that has the potential to be used against solid tumors that do not respond to other forms of therapy. In the inherited metabolic disorders division, SpringWorks is working on developing therapies for patients with rare diseases such as Niemann-Pick Type C syndrome. The company has partnered with Cydan Development, a company specializing in developing drugs for rare genetic disorders, for this purpose. In the field of neurological disorders, SpringWorks aims to develop therapies for patients with rare genetic diseases such as epilepsy and Huntington's disease. The company has initiated a collaboration with the Hospital for Sick Children in Toronto for this purpose. The company also has an innovative technology called "Biomarker Relocation" which allows for the identification of patients with certain rare diseases that are otherwise difficult to diagnose and treat. The technology is currently a significant component of SpringWorks' research and development efforts. In recent years, the company has raised capital through investments and collaborations for its business model. The funding has been based on venture capital from leading companies including Novartis Venture Fund, Pfizer Ventures, and OrbiMed. SpringWorks' business strategy also includes partnerships with other companies and research institutions. One collaboration, for example, exists with the Memorial Sloan Kettering Cancer Center, a leading institution in cancer research. The vision of SpringWorks is to play a leading role in the development of therapeutics for patients with rare diseases and to meet the medical need in this area. The company strives to improve the lives of patients with rare diseases and provide them with an optimal medication that alleviates their condition and enhances their quality of life. Overall, SpringWorks is an emerging player in the biotech industry, developing innovative therapeutics to address the needs of patients with rare diseases. With a presence in multiple medical specialties and a strong financing base, the company is poised to secure a position at the forefront of the biotech industry.
Omsättningen för förväntad SpringWorks Therapeutics är 612,33 M USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för förväntad SpringWorks Therapeutics är −62,17 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för SpringWorks Therapeutics är för närvarande −56,03. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av SpringWorks Therapeutics-aktien.
Kurs-försäljningskvoten (P/S) för SpringWorks Therapeutics är för närvarande 5,69. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för SpringWorks Therapeutics-aktien.
Eulerpool Quality Score för SpringWorks Therapeutics är 5/10.
ISIN för SpringWorks Therapeutics är US85205L1070. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för SpringWorks Therapeutics är A2PRLN. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för SpringWorks Therapeutics är SWTX. Tickersymbolen används för att handla SpringWorks Therapeutics-aktier på börsen.
SpringWorks Therapeutics aktie
SpringWorks Therapeutics Jämförbar grupp
SpringWorks Therapeutics Ticker
SpringWorks Therapeutics FIGI
Alla nyckeltal och djupgående analys av SpringWorks Therapeutics
Vår aktieanalys av SpringWorks Therapeutics-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos SpringWorks Therapeutics. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: